NO20016406L - Höyselektive reopptaksinhibitorer for norepinefrin - Google Patents

Höyselektive reopptaksinhibitorer for norepinefrin

Info

Publication number: NO20016406L
Authority: NO; Norway
Prior art keywords: norepinephrine; reuptake inhibitors; high selective; selective reuptake; inhibitors
Prior art date: 1999-07-01

Application number

NO20016406A

Other languages

English (en)

Norwegian (no)

Other versions

NO20016406D0 (no

Inventor

Erik Ho Fong Wong

Saeeduddin Ahmed

Robert Clyde Marshall

Robert Mcarthur

Duncan Paul Taylor

Lars Birgerson

Pasquale Cetera

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-01

Filing date

2001-12-28

Publication date

2002-02-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20016406(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-12-28 Application filed by Upjohn Co filed Critical Upjohn Co

2001-12-28 Publication of NO20016406D0 publication Critical patent/NO20016406D0/no

2002-02-19 Publication of NO20016406L publication Critical patent/NO20016406L/no

Links

SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229960002748 norepinephrine Drugs 0.000 title 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20016406A 1999-07-01 2001-12-28 Höyselektive reopptaksinhibitorer for norepinefrin NO20016406L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US14196899P	1999-07-01	1999-07-01
US14413199P	1999-07-16	1999-07-16
US15825699P	1999-10-06	1999-10-06
US17038199P	1999-12-13	1999-12-13
PCT/US2000/017256 WO2001001973A2 (fr)	1999-07-01	2000-06-22	Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation

Publications (2)

Publication Number	Publication Date
NO20016406D0 NO20016406D0 (no)	2001-12-28
NO20016406L true NO20016406L (no)	2002-02-19

Family

ID=27495506

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO20016406A NO20016406L (no)	1999-07-01	2001-12-28	Höyselektive reopptaksinhibitorer for norepinefrin
NO20091168A NO20091168L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091158A NO20091158L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091159A NO20091159L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
NO20091168A NO20091168L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091158A NO20091158L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091159A NO20091159L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin

Country Status (31)

Country	Link
US (18)	US6465458B1 (fr)
EP (3)	EP1196172B1 (fr)
JP (3)	JP2003503450A (fr)
KR (5)	KR100717660B1 (fr)
CN (5)	CN1660110A (fr)
AR (1)	AR035158A1 (fr)
AT (9)	ATE305306T1 (fr)
AU (2)	AU771258B2 (fr)
BR (1)	BR0012136A (fr)
CA (2)	CA2643231A1 (fr)
CL (3)	CL2008002866A1 (fr)
CO (1)	CO5190662A1 (fr)
CZ (1)	CZ299847B6 (fr)
DE (9)	DE60023043T2 (fr)
DK (4)	DK1632234T3 (fr)
EA (6)	EA011094B1 (fr)
ES (9)	ES2246485T3 (fr)
GE (1)	GEP20094798B (fr)
HK (2)	HK1049630A1 (fr)
HU (1)	HUP0201623A3 (fr)
IL (3)	IL147246A0 (fr)
MX (1)	MXPA02000562A (fr)
MY (1)	MY137348A (fr)
NO (4)	NO20016406L (fr)
NZ (2)	NZ533243A (fr)
PE (1)	PE20010684A1 (fr)
PL (1)	PL196996B1 (fr)
PT (5)	PT1632234E (fr)
SK (5)	SK286864B6 (fr)
TW (9)	TWI294779B (fr)
WO (1)	WO2001001973A2 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ533243A (en)	1999-07-01	2005-12-23	Upjohn Co	Optically pure (S.S) reboxetine in the treatment of conditions such as those involving cognitive function in which inhibiting reuptake of norepinephrine (nor adrenaline) provides relief
AR026610A1 (es) *	1999-12-01	2003-02-19	Ucb Sa	Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
NZ531172A (en)	2000-04-21	2005-07-29	Upjohn Co	Heterocyclic amine-type compounds for treating fibromyalgia and chronic fatigue syndrome
NZ522115A (en) *	2000-04-21	2004-07-30	Upjohn Co	Selected compounds for the treatment of fibromyalgia and chronic fatigue syndrome
WO2002036125A1 (fr) *	2000-10-31	2002-05-10	Head Explorer A/S	Utilisation d'inhibiteurs selectifs de recaptage de noradrenaline dans le traitement de la cephalee par tension nerveuse
BR0115301A (pt) *	2000-11-15	2004-12-14	Lilly Co Eli	Uso de um inibidor seletivo da recaptação de norepinefrina
WO2002083141A1 (fr) *	2001-04-17	2002-10-24	Pharmacia & Upjohn Company	Traitement de la fibromyalgie et du syndrome de la fatigue chronique
GB0216027D0 (en) *	2002-07-10	2002-08-21	Arachnova Therapeutics Ltd	New therapeutic use
US20040048874A1 (en) *	2001-05-22	2004-03-11	Bardsley Hazel Judith	New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
EP1627639B1 (fr) *	2001-06-19	2009-12-23	Norbert Müller	Utilisation de COX-2 inhibiteurs pour traiter les troubles affectives
US20060167074A1 (en) *	2001-06-19	2006-07-27	Norbert Muller	Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en) *	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
ATE365035T1 (de) *	2001-11-30	2007-07-15	Lilly Co Eli	Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
CA2467802A1 (fr) *	2001-12-11	2003-06-19	Eli Lilly And Company	Utilisation d'inhibiteurs de recaptage de la noradrenaline dans le traitement de la defaillance cognitive
US20040102440A1 (en) *	2002-07-01	2004-05-27	Wong Erik Ho Fong	Method of promoting smoking cessation
AU2003213009A1 (en) *	2002-02-12	2003-09-04	Cypress Bioscience, Inc.	Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030232805A1 (en) *	2002-04-24	2003-12-18	Cypress Bioscience, Inc.	Prevention and treatment of functional somatic disorders, including stress-related disorders
EP3173082A1 (fr)	2002-05-17	2017-05-31	Duke University	Procede de traitement de l'obesite
AU2003227520B9 (en) *	2002-05-30	2008-06-26	Neurosearch A/S	Triple monoamine reuptake inhibitors for the treatment of chronic pain
WO2003106441A1 (fr) *	2002-06-17	2003-12-24	Pharmacia Italia S.P.A.	Sels pharmaceutiques de reboxetine
AR040680A1 (es) *	2002-07-25	2005-04-13	Pharmacia Corp	Composicion de tabletas de liberacion sostenida
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
BR0313411A (pt) *	2002-08-14	2005-06-28	Pharmacia & Upjohn Co Llc	Uso de reboxetina para o tratamento de ondas de calor
AU2003261245A1 (en) *	2002-08-23	2004-03-11	Eli Lilly And Company	Benzyl morpholine derivatives
GB0219687D0 (en)	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
ES2315525T3 (es)	2002-08-23	2009-04-01	Eli Lilly And Company	Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
EP1558231A4 (fr) *	2002-10-03	2010-09-08	Cypress Bioscience Inc	Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
US7345096B2 (en) *	2002-10-15	2008-03-18	Wyeth	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) *	2002-10-15	2004-08-05	Deecher Darlene Coleman	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) *	2002-10-15	2004-09-16	Deecher Darlene Coleman	Novel method of treating vasomotor symptoms
US20040204411A1 (en) *	2002-12-17	2004-10-14	Pharmacia Corporation	Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP2286817A3 (fr) *	2003-01-13	2011-06-15	Edusa Pharmaceuticals, Inc	Méthode de traitement des troubles intestinaux fonctionnels
DE602004005814T2 (de) *	2003-01-13	2008-01-10	Dynogen Pharmaceuticals Inc., Waltham	Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
CA2519379A1 (fr) *	2003-04-04	2004-10-21	Dynogen Pharmaceuticals, Inc.	Methode de traitement de troubles des voies urinaires inferieures
EP1617832B1 (fr)	2003-04-29	2008-03-12	Orexigen Therapeutics, Inc.	Compositions influant sur la perte de poids
WO2004100929A1 (fr)	2003-05-12	2004-11-25	Synergia Pharma, Inc.	Formulation de threo-dops a liberation regulee
US8158149B2 (en) *	2004-05-12	2012-04-17	Chelsea Therapeutics, Inc.	Threo-DOPS controlled release formulation
WO2004105690A2 (fr) *	2003-05-23	2004-12-09	Cypress Bioscience, Inc.	Traitement de douleurs chroniques au moyen de chimiotherapie ou de radiotherapie
GB0319793D0 (en) *	2003-08-22	2003-09-24	Lilly Co Eli	Pyridinylmorpholine derivatives
EP1660065A2 (fr) *	2003-08-27	2006-05-31	Eli Lilly And Company	Traitement des troubles profonds du developpement au moyen d'inhibiteurs de la recapture de la norepinephrine
US20070010584A1 (en) *	2003-09-04	2007-01-11	Peroutka Stephen J	Compositions and methods for orthostatic intolerance
CA2537402C (fr) *	2003-09-12	2009-05-05	Pfizer Inc.	Associations comprenant des ligands alpha-2-delta et des inhibiteurs du recaptage de la serotonine et de la noradrenaline
US7365076B2 (en)	2003-10-14	2008-04-29	Wyeth	Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en)	2003-10-14	2009-04-28	Wyeth	Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7550485B2 (en) *	2003-10-14	2009-06-23	Wyeth	Substituted N-heterocycle derivatives and methods of their use
US7402698B2 (en)	2003-10-14	2008-07-22	Wyeth	Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en)	2003-10-14	2008-09-02	Wyeth	Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) *	2003-10-14	2005-06-16	Wyeth	Methods of treating vasomotor symptoms
US7531543B2 (en)	2003-10-14	2009-05-12	Wyeth	Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en)	2003-10-14	2009-02-17	Wyeth	Alkanol and cycloalkanol-amine derivatives and methods of their use
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
ES2307071T3 (es) *	2003-12-12	2008-11-16	Eli Lilly And Company	Inhibidores selectivos de la recaptacion de norepinefrina para el tratamiento de sofocos.
US7595315B2 (en)	2003-12-23	2009-09-29	Eli Lilly And Company	Morpholine derivatives as norepinephrine reuptake inhibitors
US7414052B2 (en)	2004-03-30	2008-08-19	Wyeth	Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) *	2004-03-30	2009-04-14	Wyeth	Phenylaminopropanol derivatives and methods of their use
GEP20084550B (en) *	2004-04-30	2008-11-25	Warner Lambert Co	Substituted morpholine compounds for the treatment of central nervous system disorders
KR100871272B1 (ko) *	2004-04-30	2008-11-28	화이자 인코포레이티드	모폴린 화합물
GB0409744D0 (en) *	2004-04-30	2004-06-09	Pfizer Ltd	Novel compounds
MXPA06014389A (es) *	2004-06-09	2007-02-19	Pfizer	Uso de la reboxetina para el tratamiento del dolor.
US7244765B2 (en) *	2004-06-25	2007-07-17	Cytokine Pharmasciences, Inc	Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) *	2004-08-10	2009-09-10	Pfizer Inc.	Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
SI1789021T1 (sl)	2004-08-13	2012-02-29	Boehringer Ingelheim Int	Tabletna formulacija s podaljĹˇanim sproĹˇÄŤanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol
AU2005290980A1 (en) *	2004-10-01	2006-04-13	Neurocure Ltd	Use of pharmaceutical compositions of lofepramine for the treatment of ADHD, CFS, FM and depression
US20060293309A1 (en) *	2005-03-28	2006-12-28	Dynogen Pharmaceuticals, Inc.	Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) *	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
EP2292220A3 (fr)	2005-11-22	2012-01-04	Orexigen Therapeutics, Inc.	Compositions et procédés pour augmenter la sensibilité à l'insuline
US20070253994A1 (en) *	2006-04-28	2007-11-01	Medtronic, Inc.	Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
ES2383768T3 (es) *	2006-06-28	2012-06-26	Chelsea Therapeutics Inc.	Composiciones farmacéuticas que comprenden droxidopa
MX343867B (es)	2006-11-09	2016-11-25	Orexigen Therapeutics Inc	Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
CA2680272A1 (fr)	2007-03-09	2008-09-18	Chelsea Therapeutics, Inc.	Droxidopa et composition pharmaceutique de celle-ci pour le traitement de la fibromyalgie
WO2008122019A1 (fr) *	2007-04-02	2008-10-09	Cypress Biosciences, Inc.	Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison
MX2009011858A (es) *	2007-04-30	2010-01-14	Adolor Corp	Composiciones de (-)-e-10-oh-nt y metodos para su sintesis y uso.
JP2010526820A (ja) *	2007-05-07	2010-08-05	チェルシー・セラピューティクス，インコーポレイテッド	気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
US8580776B2 (en) *	2007-07-10	2013-11-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) *	2008-02-19	2009-09-17	Adolor Corporation	(-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) *	2008-02-19	2009-09-17	Adolor Corporation	Beloxepin and analogs for the treatment of pain
US8475823B2 (en)	2008-04-18	2013-07-02	Medtronic, Inc.	Baclofen formulation in a polyorthoester carrier
US8956642B2 (en)	2008-04-18	2015-02-17	Medtronic, Inc.	Bupivacaine formulation in a polyorthoester carrier
WO2009158114A1 (fr)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Procédés pour traiter des pathologies des graisses viscérales
ES2434250T3 (es)	2008-07-24	2013-12-16	Theravance, Inc.	Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) *	2008-09-06	2010-03-18	Bionevia Pharmaceuticals, Inc.	Novel forms of reboxetine
WO2010044016A1 (fr) *	2008-10-17	2010-04-22	Pfizer Limited	Nouvelles utilisations pour l’esréboxétine et la réboxétine racémique
JP2012524098A (ja) *	2009-04-15	2012-10-11	セラヴァンス，インコーポレーテッド	３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
CN102471258A (zh) *	2009-07-13	2012-05-23	施万制药	3-苯氧基甲基吡咯烷化合物
WO2011011231A1 (fr)	2009-07-21	2011-01-27	Theravance, Inc.	Composés de la 3-phénoxyméthylpyrrolidine
EP3659604A1 (fr)	2010-01-11	2020-06-03	Nalpropion Pharmaceuticals, Inc.	Méthodes d'amaigrissementu pour des patients souffrant d'une dépression sévère
ES2533434T3 (es)	2010-10-11	2015-04-10	Theravance Biopharma R&D Ip, Llc	Inhibidores de la captación de la serotonina
US8501964B2 (en)	2010-12-03	2013-08-06	Theravance, Inc.	Serotonin reuptake inhibitors
JP5880913B2 (ja)	2011-05-17	2016-03-09	三郎佐古田	パーキンソン病の体幹症状（姿勢反射異常）の治療剤
KR20220042241A (ko)	2012-06-06	2022-04-04	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
WO2016077724A1 (fr)	2014-11-13	2016-05-19	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Carbamates (2-amino-4(arylamino)phényl)
US20190381056A1 (en)	2018-06-17	2019-12-19	Axsome Therapeutics, Inc.	Compositions for delivery of reboxetine
US20200147093A1 (en)	2018-10-15	2020-05-14	Axsome Therapeutics, Inc.	Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (fr) *	2019-12-03	2021-06-10	Axsome Therapeutics, Inc.	Utilisation de réboxétine pour traiter des troubles du système nerveux
US11020402B2 (en)	2018-10-15	2021-06-01	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
EP3693020A1 (fr) *	2019-02-08	2020-08-12	Burmaster International Group GmbH	Formulations topiques enrichies en potassium pour le soulagement de la douleur et l'aide du sommeil
BR112022010677A2 (pt) *	2019-12-03	2022-08-16	Axsome Therapeutics Inc	Uso de reboxetina para tratar transtornos do sistema nervoso

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3797494A (en)	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en)	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3742951A (en)	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
US4031894A (en)	1975-12-08	1977-06-28	Alza Corporation	Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en)	1978-01-20	1984-05-31	Erba Farmitalia	Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) *	1980-03-19	1984-08-14	Matsushita Electric Industrial Co., Ltd.	Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en)	1984-08-02	1984-09-05	Erba Farmitalia	3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) *	1984-11-22	1988-05-11	Erba Farmitalia	Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en)	1985-03-26	1986-06-24	Serotonin Industries Of Charleston	Method and compositions for controlling pain, depression and sedation
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
ZA921292B (en)	1991-02-25	1993-08-23	Lilly Co Eli	Treatment of lower urinary tract disorders.
US5281624A (en)	1991-09-27	1994-01-25	Eli Lilly And Company	N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en)	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en)	1993-11-24	1998-11-11	Lilly Co Eli	Pharmaceutical composition for treatment of incontinence
IL111786A0 (en)	1993-12-01	1995-01-24	Max Planck Gesellschaft	Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (fr) *	1994-06-16	1997-06-03	David Taiwai Wong	Potentialisation des effets de medicaments
ZA958725B (en)	1994-10-20	1997-04-16	Lilly Co Eli	Treatment of disorders with duloxetine
WO1997035584A1 (fr)	1996-03-25	1997-10-02	Eli Lilly And Company	Procede de traitement de la douleur
CZ296263B6 (cs)	1996-03-25	2006-02-15	Eli Lilly And Company	Farmaceutická kompozice pro lécení bolesti a jejípouzití
US5914333A (en) *	1996-07-31	1999-06-22	Novo Nordisk A/S	Treatment of psychotic disorders
US6479074B2 (en)	1996-10-24	2002-11-12	Pharmaceutical Applications Associates Llc	Methods and transdermal compositions for pain relief
US20020015713A1 (en)	1996-10-24	2002-02-07	Murdock Robert W.	Methods and transdermal compositions for pain relief
WO2000000120A1 (fr)	1998-06-29	2000-01-06	Pharmaceuticals Applications Asociates, Llc	Compositions antalgiques transdermiques et leurs methodes d'administration
US6290986B1 (en)	1996-10-24	2001-09-18	Pharmaceutical Applications Associates, Llc	Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en)	1996-10-24	2003-06-03	Pharmaceutical Applications Associates Llc	Methods and transdermal compositions for pain relief
ATE172117T1 (de)	1996-11-27	1998-10-15	Pfleger R Chem Fab	Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
KR20000057548A (ko)	1996-12-13	2000-09-25	알프레드 엘. 미첼슨	광학적 전송물질 및 결합재
JP2002503224A (ja)	1997-04-11	2002-01-29	エリリリーアンドカンパニー	疼痛を処置するための組成物
US5942530A (en)	1997-08-28	1999-08-24	Eli Lilly And Company	Method for treating pain
AU5155198A (en)	1997-08-28	1999-03-22	Robert Murdock	Method and composition for transdermal administration of pharmacologic agent
US6622036B1 (en) *	2000-02-09	2003-09-16	Cns Response	Method for classifying and treating physiologic brain imbalances using quantitative EEG
AU9214498A (en)	1997-09-23	1999-04-12	Eli Lilly And Company	Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) *	1997-09-23	2003-06-16	Елі Ліллі Енд Компані	Спосіб лікування розладу поведінки
UA56257C2 (uk)	1997-09-23	2003-05-15	Елі Ліллі Енд Компані	Спосіб лікування неадекватної визивної поведінки
CA2306233A1 (fr)	1997-10-17	1999-04-29	Eli Lilly And Company	Potentialisation de produits pharmaceutiques
US6586427B2 (en) *	1998-04-09	2003-07-01	Pharmacia & Upjohn Company	Treatments for nervous disorders
JP2002511414A (ja) *	1998-04-09	2002-04-16	ファルマシア・アンド・アップジョン・カンパニー	神経疾患のための新しい治療
IT1305322B1 (it)	1998-04-23	2001-05-04	Pharmacia & Upjohn Spa	Uso di reboxetina per il trattamento di disturbi nervosi
BR9909559A (pt) *	1998-05-08	2000-12-19	Upjohn Co	Novas combinações de drogas
US6331571B1 (en) *	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
NZ533243A (en) *	1999-07-01	2005-12-23	Upjohn Co	Optically pure (S.S) reboxetine in the treatment of conditions such as those involving cognitive function in which inhibiting reuptake of norepinephrine (nor adrenaline) provides relief
GB2355191A (en)	1999-10-12	2001-04-18	Laxdale Ltd	Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv)	1999-12-23	1999-12-23	Pharmacia & Upjohn Ab	New formulation, use and method
JP2003523382A (ja) *	2000-02-24	2003-08-05	ファルマシア・アンド・アップジョン・カンパニー	新規な薬物の組合せ
US20050096349A1 (en) *	2003-11-03	2005-05-05	University Of Florida	Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

2000
- 2000-06-22 NZ NZ533243A patent/NZ533243A/en unknown
- 2000-06-22 ES ES04013381T patent/ES2246485T3/es not_active Expired - Lifetime
- 2000-06-22 AU AU56337/00A patent/AU771258B2/en not_active Ceased
- 2000-06-22 DK DK05111704T patent/DK1632234T3/da active
- 2000-06-22 PT PT05111704T patent/PT1632234E/pt unknown
- 2000-06-22 EA EA200700232A patent/EA011094B1/ru not_active IP Right Cessation
- 2000-06-22 ES ES04013383T patent/ES2247572T3/es not_active Expired - Lifetime
- 2000-06-22 EA EA200801806A patent/EA200801806A1/ru unknown
- 2000-06-22 SK SK50022-2007A patent/SK286864B6/sk not_active IP Right Cessation
- 2000-06-22 CN CN2004101045241A patent/CN1660110A/zh active Pending
- 2000-06-22 ES ES04025514T patent/ES2246488T3/es not_active Expired - Lifetime
- 2000-06-22 GE GEAP200011110A patent/GEP20094798B/en unknown
- 2000-06-22 ES ES04023888T patent/ES2246487T3/es not_active Expired - Lifetime
- 2000-06-22 CA CA002643231A patent/CA2643231A1/fr not_active Abandoned
- 2000-06-22 EA EA200400589A patent/EA006652B1/ru not_active IP Right Cessation
- 2000-06-22 PT PT04013382T patent/PT1459750E/pt unknown
- 2000-06-22 SK SK50021-2007A patent/SK286667B6/sk not_active IP Right Cessation
- 2000-06-22 DE DE60023043T patent/DE60023043T2/de not_active Expired - Lifetime
- 2000-06-22 AT AT04023888T patent/ATE305306T1/de not_active IP Right Cessation
- 2000-06-22 DE DE60035232T patent/DE60035232T2/de not_active Expired - Lifetime
- 2000-06-22 EA EA200501496A patent/EA008381B1/ru not_active IP Right Cessation
- 2000-06-22 EP EP00941659A patent/EP1196172B1/fr not_active Expired - Lifetime
- 2000-06-22 DE DE60022917T patent/DE60022917T2/de not_active Expired - Fee Related
- 2000-06-22 KR KR1020057009371A patent/KR100717660B1/ko not_active Expired - Fee Related
- 2000-06-22 DE DE60022692T patent/DE60022692T2/de not_active Expired - Lifetime
- 2000-06-22 MX MXPA02000562A patent/MXPA02000562A/es active IP Right Grant
- 2000-06-22 DE DE60020613T patent/DE60020613T2/de not_active Expired - Lifetime
- 2000-06-22 DK DK00941659T patent/DK1196172T3/da active
- 2000-06-22 KR KR1020097015713A patent/KR100948757B1/ko not_active Expired - Fee Related
- 2000-06-22 KR KR1020097015714A patent/KR20090087135A/ko not_active Ceased
- 2000-06-22 PT PT04013379T patent/PT1459748E/pt unknown
- 2000-06-22 DE DE60019473T patent/DE60019473T2/de not_active Expired - Lifetime
- 2000-06-22 WO PCT/US2000/017256 patent/WO2001001973A2/fr active Application Filing
- 2000-06-22 DE DE60022916T patent/DE60022916T2/de not_active Expired - Fee Related
- 2000-06-22 US US09/599,213 patent/US6465458B1/en not_active Expired - Lifetime
- 2000-06-22 AT AT04013381T patent/ATE305788T1/de not_active IP Right Cessation
- 2000-06-22 AT AT04025514T patent/ATE305307T1/de not_active IP Right Cessation
- 2000-06-22 EP EP09161068A patent/EP2090312A1/fr not_active Withdrawn
- 2000-06-22 AT AT05111704T patent/ATE364386T1/de not_active IP Right Cessation
- 2000-06-22 BR BR0012136-3A patent/BR0012136A/pt not_active Application Discontinuation
- 2000-06-22 SK SK50024-2007A patent/SK286669B6/sk not_active IP Right Cessation
- 2000-06-22 DE DE60026627T patent/DE60026627T2/de not_active Expired - Fee Related
- 2000-06-22 KR KR1020067017835A patent/KR100935277B1/ko not_active Expired - Fee Related
- 2000-06-22 ES ES04013382T patent/ES2242175T3/es not_active Expired - Lifetime
- 2000-06-22 JP JP2001507467A patent/JP2003503450A/ja active Pending
- 2000-06-22 DK DK04013381T patent/DK1459749T3/da active
- 2000-06-22 CZ CZ20014625A patent/CZ299847B6/cs not_active IP Right Cessation
- 2000-06-22 KR KR1020017016963A patent/KR100704319B1/ko not_active Expired - Fee Related
- 2000-06-22 CN CNB2004101045256A patent/CN1289090C/zh not_active Expired - Fee Related
- 2000-06-22 NZ NZ515885A patent/NZ515885A/en unknown
- 2000-06-22 CN CN2004101045237A patent/CN1660109A/zh active Pending
- 2000-06-22 CN CN2004101045222A patent/CN1660108A/zh active Pending
- 2000-06-22 SK SK1938-2001A patent/SK286104B6/sk not_active IP Right Cessation
- 2000-06-22 PL PL352252A patent/PL196996B1/pl not_active IP Right Cessation
- 2000-06-22 PT PT04013383T patent/PT1459751E/pt unknown
- 2000-06-22 DE DE60026704T patent/DE60026704T2/de not_active Expired - Lifetime
- 2000-06-22 AT AT00941659T patent/ATE320257T1/de not_active IP Right Cessation
- 2000-06-22 EP EP09161069A patent/EP2087892A3/fr not_active Withdrawn
- 2000-06-22 IL IL14724600A patent/IL147246A0/xx not_active IP Right Cessation
- 2000-06-22 HU HU0201623A patent/HUP0201623A3/hu unknown
- 2000-06-22 PT PT00941659T patent/PT1196172E/pt unknown
- 2000-06-22 EA EA200801805A patent/EA200801805A1/ru unknown
- 2000-06-22 CA CA002375908A patent/CA2375908C/fr not_active Expired - Fee Related
- 2000-06-22 DK DK04013382T patent/DK1459750T3/da active
- 2000-06-22 AT AT04013383T patent/ATE304358T1/de not_active IP Right Cessation
- 2000-06-22 CN CNB008084858A patent/CN1205935C/zh not_active Expired - Fee Related
- 2000-06-22 AT AT04025513T patent/ATE319453T1/de not_active IP Right Cessation
- 2000-06-22 SK SK50023-2007A patent/SK286668B6/sk not_active IP Right Cessation
- 2000-06-22 ES ES04013379T patent/ES2239311T3/es not_active Expired - Lifetime
- 2000-06-22 EA EA200200111A patent/EA005029B1/ru not_active IP Right Cessation
- 2000-06-22 AT AT04013379T patent/ATE292971T1/de not_active IP Right Cessation
- 2000-06-22 ES ES05111704T patent/ES2285645T3/es not_active Expired - Lifetime
- 2000-06-22 AT AT04013382T patent/ATE296634T1/de not_active IP Right Cessation
- 2000-06-22 ES ES04025513T patent/ES2258251T3/es not_active Expired - Lifetime
- 2000-06-22 ES ES00941659T patent/ES2258010T3/es not_active Expired - Lifetime
- 2000-06-27 MY MYPI20002899A patent/MY137348A/en unknown
- 2000-06-28 PE PE2000000664A patent/PE20010684A1/es not_active Application Discontinuation
- 2000-06-30 AR ARP000103350A patent/AR035158A1/es unknown
- 2000-07-04 CO CO00049691A patent/CO5190662A1/es not_active Application Discontinuation
- 2000-09-05 TW TW094142131A patent/TWI294779B/zh active
- 2000-09-05 TW TW092137686A patent/TW200407146A/zh unknown
- 2000-09-05 TW TW094142128A patent/TWI298255B/zh not_active IP Right Cessation
- 2000-09-05 TW TW097124457A patent/TW200920378A/zh unknown
- 2000-09-05 TW TW097124426A patent/TW200914027A/zh unknown
- 2000-09-05 TW TW094142132A patent/TWI293250B/zh active
- 2000-09-05 TW TW089113086A patent/TWI245631B/zh not_active IP Right Cessation
- 2000-09-05 TW TW094142126A patent/TWI298254B/zh not_active IP Right Cessation
- 2000-09-05 TW TW097124378A patent/TW200922594A/zh unknown
2001
- 2001-12-14 US US10/020,261 patent/US6703389B2/en not_active Expired - Fee Related
- 2001-12-28 NO NO20016406A patent/NO20016406L/no unknown
2002
- 2002-01-04 US US10/099,334 patent/US6642235B2/en not_active Expired - Fee Related
- 2002-01-04 US US10/037,344 patent/US6610690B2/en not_active Expired - Lifetime
- 2002-01-23 US US10/055,663 patent/US6987107B2/en not_active Expired - Fee Related
- 2002-09-26 US US10/255,450 patent/US20030040464A1/en not_active Abandoned
2003
- 2003-03-14 HK HK03101844A patent/HK1049630A1/xx not_active IP Right Cessation
- 2003-09-24 US US10/669,611 patent/US20040058925A1/en not_active Abandoned
2004
- 2004-01-16 US US10/758,864 patent/US7317011B2/en not_active Expired - Fee Related
- 2004-05-18 AU AU2004202096A patent/AU2004202096B2/en not_active Ceased
2005
- 2005-09-30 HK HK05108676A patent/HK1076723A1/xx not_active IP Right Cessation
2006
- 2006-02-07 US US11/348,948 patent/US20060142289A1/en not_active Abandoned
- 2006-02-07 US US11/349,022 patent/US7241762B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/349,331 patent/US7338953B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/349,373 patent/US7276503B2/en not_active Expired - Fee Related
- 2006-02-22 JP JP2006045459A patent/JP2006143749A/ja active Pending
- 2006-07-28 US US11/460,775 patent/US20060264436A1/en not_active Abandoned
- 2006-08-02 JP JP2006210418A patent/JP2006321815A/ja active Pending
2007
- 2007-10-30 US US11/928,917 patent/US7723334B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/928,980 patent/US20080103147A1/en not_active Abandoned
- 2007-10-30 US US11/928,781 patent/US20080103145A1/en not_active Abandoned
- 2007-10-30 US US11/928,812 patent/US20080096890A1/en not_active Abandoned
- 2007-11-20 IL IL187512A patent/IL187512A0/en unknown
- 2007-11-20 IL IL187513A patent/IL187513A0/en unknown
2008
- 2008-09-26 CL CL2008002866A patent/CL2008002866A1/es unknown
- 2008-09-26 CL CL2008002868A patent/CL2008002868A1/es unknown
- 2008-09-26 CL CL2008002867A patent/CL2008002867A1/es unknown
2009
- 2009-03-18 NO NO20091168A patent/NO20091168L/no not_active Application Discontinuation
- 2009-03-18 NO NO20091158A patent/NO20091158L/no unknown
- 2009-03-18 NO NO20091159A patent/NO20091159L/no unknown
- 2009-04-27 US US12/430,244 patent/US20090247528A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60022917T2 (de)	2006-06-29
DK1459749T3 (da)	2006-01-09
US6610690B2 (en)	2003-08-26
EA008381B1 (ru)	2007-04-27
ATE305306T1 (de)	2005-10-15
DE60023043T2 (de)	2006-06-14
CL2008002867A1 (es)	2009-01-09
WO2001001973A2 (fr)	2001-01-11
CA2375908A1 (fr)	2001-01-11
DE60026627T2 (de)	2007-02-01
DE60022916D1 (de)	2006-02-09
KR100935277B1 (ko)	2010-01-06
DE60019473T2 (de)	2006-02-23
DE60035232T2 (de)	2008-02-14
CL2008002868A1 (es)	2009-01-09
US20030040464A1 (en)	2003-02-27
EP2090312A1 (fr)	2009-08-19
DE60020613D1 (de)	2005-07-07
PT1459751E (pt)	2005-11-30
TW200607509A (en)	2006-03-01
EP1196172A2 (fr)	2002-04-17
KR20060099544A (ko)	2006-09-19
SK286669B6 (sk)	2009-03-05
TW200607510A (en)	2006-03-01
US7317011B2 (en)	2008-01-08
SK286668B6 (sk)	2009-03-05
IL187512A0 (en)	2008-06-05
US20090247528A1 (en)	2009-10-01
HUP0201623A2 (en)	2002-09-28
WO2001001973A3 (fr)	2002-01-17
EA005029B1 (ru)	2004-10-28
ES2285645T3 (es)	2007-11-16
TWI298255B (en)	2008-07-01
ES2239311T3 (es)	2005-09-16
NZ515885A (en)	2004-08-27
EP1196172B1 (fr)	2006-03-15
DE60023043D1 (de)	2006-02-16
EA006652B1 (ru)	2006-02-24
US7338953B2 (en)	2008-03-04
CN1660109A (zh)	2005-08-31
PE20010684A1 (es)	2001-06-24
NZ533243A (en)	2005-12-23
CN1660111A (zh)	2005-08-31
GEP20094798B (en)	2009-10-26
ATE319453T1 (de)	2006-03-15
TW200607511A (en)	2006-03-01
PT1632234E (pt)	2007-07-09
DE60026704T2 (de)	2006-10-19
KR100948757B1 (ko)	2010-03-23
ATE320257T1 (de)	2006-04-15
TWI245631B (en)	2005-12-21
AU2004202096A1 (en)	2004-06-10
ATE304358T1 (de)	2005-09-15
CN1660108A (zh)	2005-08-31
HK1049630A1 (en)	2003-05-23
US20020128173A1 (en)	2002-09-12
ES2242175T3 (es)	2005-11-01
CN1660110A (zh)	2005-08-31
US20060128705A1 (en)	2006-06-15
PT1459750E (pt)	2005-08-31
ES2246485T3 (es)	2006-02-16
US6465458B1 (en)	2002-10-15
HK1076723A1 (en)	2006-01-27
MY137348A (en)	2009-01-30
EA200801805A1 (ru)	2008-12-30
IL187513A0 (en)	2008-06-05
IL147246A0 (en)	2002-08-14
US7723334B2 (en)	2010-05-25
DE60035232D1 (de)	2007-07-26
DK1459750T3 (da)	2005-08-15
US6703389B2 (en)	2004-03-09
EP2087892A2 (fr)	2009-08-12
US7276503B2 (en)	2007-10-02
US20080096890A1 (en)	2008-04-24
CN1379672A (zh)	2002-11-13
AR035158A1 (es)	2004-05-05
CZ20014625A3 (cs)	2002-08-14
DE60020613T2 (de)	2006-03-16
TW200607512A (en)	2006-03-01
ATE296634T1 (de)	2005-06-15
CA2375908C (fr)	2006-05-30
EA200400589A1 (ru)	2004-12-30
EA200801806A1 (ru)	2008-12-30
ATE292971T1 (de)	2005-04-15
DE60022692T2 (de)	2006-06-22
TWI294779B (en)	2008-03-21
AU5633700A (en)	2001-01-22
KR20050053799A (ko)	2005-06-08
CO5190662A1 (es)	2002-08-29
US20060135521A1 (en)	2006-06-22
NO20016406D0 (no)	2001-12-28
TW200407146A (en)	2004-05-16
ES2258251T3 (es)	2006-08-16
US6642235B2 (en)	2003-11-04
BR0012136A (pt)	2002-06-11
CA2643231A1 (fr)	2001-01-11
CL2008002866A1 (es)	2009-01-09
DE60022916T2 (de)	2006-07-06
DE60026627D1 (de)	2006-05-04
DK1196172T3 (da)	2006-06-19
DE60022917D1 (de)	2006-02-09
ATE305307T1 (de)	2005-10-15
NO20091159L (no)	2002-02-19
PL196996B1 (pl)	2008-02-29
PT1459748E (pt)	2005-08-31
TW200922594A (en)	2009-06-01
DE60019473D1 (de)	2005-05-19
ES2246488T3 (es)	2006-02-16
KR100717660B1 (ko)	2007-05-15
US20040147614A1 (en)	2004-07-29
JP2006143749A (ja)	2006-06-08
US20060264436A1 (en)	2006-11-23
CN1205935C (zh)	2005-06-15
US20080103147A1 (en)	2008-05-01
JP2006321815A (ja)	2006-11-30
EP2087892A3 (fr)	2009-09-30
US20080103146A1 (en)	2008-05-01
US20060142289A1 (en)	2006-06-29
ATE364386T1 (de)	2007-07-15
PT1196172E (pt)	2006-05-31
KR20090087134A (ko)	2009-08-14
EA011094B1 (ru)	2008-12-30
KR20090087135A (ko)	2009-08-14
EA200200111A1 (ru)	2002-06-27
ATE305788T1 (de)	2005-10-15
TWI298254B (en)	2008-07-01
EA200501496A1 (ru)	2006-06-30
TW200920378A (en)	2009-05-16
US20080103145A1 (en)	2008-05-01
ES2247572T3 (es)	2006-03-01
DK1632234T3 (da)	2007-09-17
NO20091158L (no)	2002-02-19
US7241762B2 (en)	2007-07-10
HUP0201623A3 (en)	2004-12-28
EA200700232A1 (ru)	2007-06-29
DE60022692D1 (de)	2005-10-20
KR100704319B1 (ko)	2007-04-09
US20060135520A1 (en)	2006-06-22
SK286864B6 (sk)	2009-06-05
MXPA02000562A (es)	2002-07-02
AU2004202096B2 (en)	2005-10-20
CN1289090C (zh)	2006-12-13
US20020086864A1 (en)	2002-07-04
US20040058925A1 (en)	2004-03-25
SK19382001A3 (sk)	2002-07-02
ES2258010T3 (es)	2006-08-16
TW200914027A (en)	2009-04-01
DE60026704D1 (de)	2006-05-11
WO2001001973A8 (fr)	2001-05-17
US20020107249A1 (en)	2002-08-08
US6987107B2 (en)	2006-01-17
US20020061910A1 (en)	2002-05-23
AU771258B2 (en)	2004-03-18
SK286104B6 (sk)	2008-03-05
JP2003503450A (ja)	2003-01-28
KR20020015363A (ko)	2002-02-27
NO20091168L (no)	2002-02-19
SK286667B6 (sk)	2009-03-05
ES2246487T3 (es)	2006-02-16
PL352252A1 (en)	2003-08-11
TWI293250B (en)	2008-02-11
CZ299847B6 (cs)	2008-12-10

Publication	Publication Date	Title
NO20016406L (no)	2002-02-19	Höyselektive reopptaksinhibitorer for norepinefrin
NO20021239L (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
DK2253620T3 (da)	2014-03-31	Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20021659L (no)	2002-04-08	Biaryleterderivater nyttige som monoamin reopptaksinhibitorer
ATE524441T1 (de)	2011-09-15	Vla-4-inhibitoren
CY2014022I1 (el)	2015-12-09	Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
NO20034307D0 (no)	2003-09-26	Cyklopropylindol-derivater som selektive serotonin- gjenopptaksinhibitorer
NO20030867D0 (no)	2003-02-25	Hydroksamderivater anvendelig som deacetylaseinhibitorer
DK1140840T3 (da)	2006-07-31	omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
PT1181017E (pt)	2003-06-30	Inibidores de metaloproteases
NO20015065L (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
PT1226136E (pt)	2005-04-29	Inibidores da tirosina quinase
DK1460066T3 (da)	2009-11-02	Piperazinforbindelse som tachykinin-inhibitorer
PT1194404E (pt)	2006-08-31	Inibidores de aspartil-protease
NO20030842D0 (no)	2003-02-24	Fenoksybenzylamin-derivater som selektive serotonin- gjenopptaksinhibitorer
SI1212320T1 (en)	2005-10-31	Phenylpiperazines as serotonin reuptake inhibitors
DK1272488T3 (da)	2006-07-17	Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
PT1339695E (pt)	2006-08-31	Inibidores da farnesiltransferase
PT9674T (pt)	2001-06-29	Embalagem para cigarros
PT9699T (pt)	2001-09-27	Dispositivo retrovisor para ciclistas
ES1046497Y (es)	2001-06-01	Escurridor para mochos
ES1045898Y (es)	2001-04-16	Placas para revestimientos.
ES1043040Y (es)	2000-04-01	Envoltorio para flexometros.
IT249628Y1 (it)	2003-05-20	Dispositivo portafilo per orditoi